{"schema":"rootz.ai/filing-signals/v1","query":{"ticker":"MMM","limit":50},"count":50,"signals":[{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ogram;Reviews the Companys compensation policies and practices and, based on its review and expertise, provides an assessment as to whether such policies and practices are reasonably likely to have a material adverse effect on the Company;Reviews and provides an independent assessment of materials provided to the Committee by management of the Company;Provides advice and recommendations to the Committee regarding the co","filed_date":"2026-03-25","accession":"0000066740-26-000151","full_text":"https://origin.rootz.global/static/filing/0000066740-26-000151.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":122,"context":"and its shareholders to retain PwC. | | | | | | FOR | | Executive compensation | | | | | | Advisory approval of executive compensation (page 48)Approve, on an advisory basis, the compensation of our Named Executive Officers (NEOs).Our executive compensation program appropriately aligns our executives compensation with the performance of the Company and its business units, as well as their individual performance. | | |","filed_date":"2026-03-25","accession":"0000066740-26-000151","full_text":"https://origin.rootz.global/static/filing/0000066740-26-000151.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":95,"context":"ocations or industries in which the Company operates. Further escalation of specific trade tensions, including those between the U.S. and China, or more broadly in global trade conflict, could have a material adverse effect on the Company's business and operations around the world. The Company's business is also impacted by social, political, and labor conditions in locations in which the Company or its suppliers or cus","filed_date":"2026-02-03","accession":"0000066740-26-000014","full_text":"https://origin.rootz.global/static/filing/0000066740-26-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":22,"context":"he CAE legal settlement. Cash Flows from Investing Activities:Investments in PP&E enable growth across many diverse markets, helping to meet product demand and increasing manufacturing efficiency. 3M invested $0.9 billion on PP&E in 2025. The Company expects 2026 capital spending to be approximately $1.1 billion as 3M continues to invest in growth, productivity and sustainability.34Table of ContentsPurchases of market","filed_date":"2026-02-03","accession":"0000066740-26-000014","full_text":"https://origin.rootz.global/static/filing/0000066740-26-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":52,"context":"matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations, and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in","filed_date":"2025-10-21","accession":"0000066740-25-000089","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000089.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":18,"context":"he CAE legal settlement. Cash Flows from Investing Activities:Investments in PP&E enable growth across many diverse markets, helping to meet product demand and increasing manufacturing efficiency. 3M invested $0.7 billion on PP&E in the first nine months of 2025. The Company expects 2025 capital spending to be approximately $0.9 billion as 3M continues to invest in growth, productivity and sustainability.3M invests in","filed_date":"2025-10-21","accession":"0000066740-25-000089","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000089.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":54,"context":"matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations, and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in","filed_date":"2025-07-18","accession":"0000066740-25-000063","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":18,"context":"ents. 57Table of ContentsCash Flows from Investing Activities:Investments in PP&E enable growth across many diverse markets, helping to meet product demand and increasing manufacturing efficiency. 3M invested $0.4 billion on PP&E in the first six months of 2025. The Company expects 2025 capital spending to be approximately $1.0 billion as 3M continues to invest in growth, productivity and sustainability.3M invests in","filed_date":"2025-07-18","accession":"0000066740-25-000063","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000063.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":52,"context":"matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations, and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in","filed_date":"2025-04-22","accession":"0000066740-25-000039","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":19,"context":"ows from Investing Activities:Investments in property, plant and equipment (PP&E) enable growth across many diverse markets, helping to meet product demand and increasing manufacturing efficiency. 3M invested $0.2 billion on PP&E in the first three months of 2025. The Company expects 2025 capital spending to be approximately $1.1 billion as 3M continues to invest in growth, productivity and sustainability.3M invests i","filed_date":"2025-04-22","accession":"0000066740-25-000039","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000039.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"t of their DSUs as follows:a single lump sum during the month of January in the first or second year following the year in which they leave the Board; orin a series of three, five, or ten annual installments beginning during the month of January in the first year after they leave the Board.2024 director compensation tableThe table below shows the amounts earned by our non-employee directors in 2024.","filed_date":"2025-03-26","accession":"0000066740-25-000029","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":27,"context":"ogram;Reviews the Companys compensation policies and practices and, based on its review and expertise, provides an assessment as to whether such policies and practices are reasonably likely to have a material adverse effect on the Company;Reviews and provides an independent assessment of materials provided to the Committee by management of the Company;Provides advice and recommendations to the Committee regarding the co","filed_date":"2025-03-26","accession":"0000066740-25-000029","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":160,"context":"y and its shareholders to retain PwC. | | | | | | FOR | | Executive compensation | | | | | | Advisory approval of executive compensation(page 56)Approve, on an advisory basis, the compensation of our Named Executive Officers (NEOs).Our executive compensation program appropriately aligns our executives compensation with the performance of the Company and its business units as well as their individual performance. | | | |","filed_date":"2025-03-26","accession":"0000066740-25-000029","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000029.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":13,"context":"In addition, 3M recorded certain pre-tax adjustments, accelerated depreciation and other charges related to these actions of $44million and $4million in 2024 and 2023, respectively. 3M also recorded restructuring charges in 2023 and 2024 for PFAS exit actions and in 2022 for divestiture-related restructuring actions as further described in Note 6 which are part of the manufactured PFAS products and divestiture-relate","filed_date":"2025-02-05","accession":"0000066740-25-000006","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":94,"context":"ocations or industries in which the Company operates. Further escalation of specific trade tensions, including those between the U.S. and China, or more broadly in global trade conflict, could have a material adverse effect on the Company's business and operations around the world. The Company's business is also impacted by social, political, and labor conditions in locations in which the Company or its suppliers or cus","filed_date":"2025-02-05","accession":"0000066740-25-000006","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":40,"context":"and providing equal opportunities for advancement. 3M supports these values with an internal CEO Inclusion Council, a forum led by senior management to advance inclusion. Since 2020, the Company has invested $50 million to address opportunity gaps through workforce development initiatives in the communities in which its employees live and 3M business operates.  Compensation and Benefits: 3M invests in a professional","filed_date":"2025-02-05","accession":"0000066740-25-000006","full_text":"https://origin.rootz.global/static/filing/0000066740-25-000006.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":38,"context":"matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in","filed_date":"2024-10-22","accession":"0000066740-24-000101","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000101.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":30,"context":"ows from Investing Activities:Investments in property, plant and equipment (PP&E) enable growth across many diverse markets, helping to meet product demand and increasing manufacturing efficiency. 3M invested $890 million on PP&E in the first nine months of 2024. 3M invests in renewal and maintenance programs, which pertain to cost reduction, cycle time, maintaining and renewing current capacity, eliminating pollution","filed_date":"2024-10-22","accession":"0000066740-24-000101","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000101.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":35,"context":"matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in","filed_date":"2024-07-26","accession":"0000066740-24-000080","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000080.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":30,"context":"ows from Investing Activities:Investments in property, plant and equipment (PP&E) enable growth across many diverse markets, helping to meet product demand and increasing manufacturing efficiency. 3M invested $644 million on PP&E in the first six months of 2024. 3M invests in renewal and maintenance programs, which pertain to cost reduction, cycle time, maintaining and renewing current capacity, eliminating pollution,","filed_date":"2024-07-26","accession":"0000066740-24-000080","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000080.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":35,"context":"matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in","filed_date":"2024-04-30","accession":"0000066740-24-000053","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":20,"context":"al Statements in 3M's 2023 Annual Report on Form 10-K for more information on relevant pre-2024 divestitures.Previously Announced Divestitures: On April 1, 2024, 3M completed the previously announced separation of its Health Care business (the Separation) through a pro rata distribution of 80.1% of the outstanding shares of Solventum Corporation (Solventum) to 3M stockholders. This spin-off transaction was int","filed_date":"2024-04-30","accession":"0000066740-24-000053","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000053.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":28,"context":"ogram;Reviews the Companys compensation policies and practices and, based on its review and expertise, provides an assessment as to whether such policies and practices are reasonably likely to have a material adverse effect on the Company;Reviews and provides an independent assessment of materials provided to the Committee by management of the Company;Provides advice and recommendations to the Committee regarding the co","filed_date":"2024-03-27","accession":"0000066740-24-000037","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":190,"context":"ing growth opportunitiesDrove Adjusted Earnings per Share of $9.84 and significantly increased Free Cash Flow 30% year-on-year to $6.3 billion, with robust conversion of 123%, up 37 ppts year-on-year*Invested $3.5 billion in research and development and capital expenditures to position 3M for the future, including investments focused on growth, productivity, and sustainabilityFocused on using material science to make","filed_date":"2024-03-27","accession":"0000066740-24-000037","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000037.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":13,"context":"and R&D. Cost of Sales: Cost of sales, measured as a percent of sales, increased in 2023 when compared to 2022. Increases were primarily due to investments in growth, productivity and sustainability; restructuring charges, and carryover impact of higher energy cost inflation partially offset by lower year-on-year net costs for significant litigation to address certain PFAS-related matters at 3M's Zwijndrecht, Belgium","filed_date":"2024-02-07","accession":"0000066740-24-000016","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":72,"context":") multi-district litigation and some of which are pending in other jurisdictions. Various factors or developments in these and other disclosed actions could result in future charges that could have a material adverse effect on 3M. For example, we recorded a pre-tax charge of $897 million, inclusive of legal fees and other related obligations, in the first quarter of 2018 with respect to the settlement of a matter brough","filed_date":"2024-02-07","accession":"0000066740-24-000016","full_text":"https://origin.rootz.global/static/filing/0000066740-24-000016.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":17,"context":"t quarter of 2023 and continuing through 2025 is expected to impact approximately 8,500 positions worldwide with an expected pre-tax charge of $700million to $900million over that period. The related restructuring charges for periods presented were recorded in the income (loss) statement as follows: | | | | | | | | | | | | | | | | | | (Millions) | | Three months ended September 30, 2023 | | Nine months ended September","filed_date":"2023-10-24","accession":"0000066740-23-000092","full_text":"https://origin.rootz.global/static/filing/0000066740-23-000092.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":33,"context":"matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in","filed_date":"2023-10-24","accession":"0000066740-23-000092","full_text":"https://origin.rootz.global/static/filing/0000066740-23-000092.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":16,"context":"t quarter of 2023 and continuing through 2025 is expected to impact approximately 8,500 positions worldwide with an expected pre-tax charge of $700million to $900million over that period. The related restructuring charges for periods presented were recorded in the income (loss) statement as follows: | | | | | | | | | | | | | | | | | | (Millions) | | Three months ended June 30, 2023 | | Six months ended June 30, 2023 |","filed_date":"2023-07-25","accession":"0000066740-23-000058","full_text":"https://origin.rootz.global/static/filing/0000066740-23-000058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":32,"context":"matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in","filed_date":"2023-07-25","accession":"0000066740-23-000058","full_text":"https://origin.rootz.global/static/filing/0000066740-23-000058.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":33,"context":"matter. However, even when a loss or range of loss is not probable and reasonably estimable, developments in, or the ultimate resolution of, a matter could be material to the Company and could have a material adverse effect on the Company, its consolidated financial position, results of operations and cash flows. In addition, future adverse rulings or developments, or settlements in, one or more matters could result in","filed_date":"2023-04-25","accession":"0000066740-23-000028","full_text":"https://origin.rootz.global/static/filing/0000066740-23-000028.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":16,"context":"ted to compensation programs** Following completion of a recent compensation risk assessment, the Company concluded that none of its compensation policies and practices is reasonably likely to have a material adverse effect on the Company. In connection with this assessment, the Company completed an inventory of its executive and non-executive compensation programs globally, with particular emphasis on incentive compens","filed_date":"2023-03-22","accession":"0001308179-23-000288","full_text":"https://origin.rootz.global/static/filing/0001308179-23-000288.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":175,"context":"parable GAAP financial measures. | | |  |  |  |  |  | | |  Innovating for the future |  |  Continued to innovate for customers and capitalize on growth, productivity, and sustainability opportunities Invested $3.6 billion in the combination of research and development and capital expenditures to position 3M for the future, including investments focused on growth, productivity, and sustainability particularly water and","filed_date":"2023-03-22","accession":"0001308179-23-000288","full_text":"https://origin.rootz.global/static/filing/0001308179-23-000288.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":32,"context":"such as disposable respirators has experienced a decline from prior levels. 3M is not able to predict the impact of unexpected events, such as the COVID-19 pandemic, and unexpected events may have a material adverse effect on 3M's consolidated results of operations or financial condition. 10 [T](#i33486be8de144b99aa444b972b691100_366)[able of](#i33486be8de144b99aa444b972b691100_366)[Contents](#i33486be8de144b99aa444b97","filed_date":"2023-02-08","accession":"0000066740-23-000014","full_text":"https://origin.rootz.global/static/filing/0000066740-23-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":13,"context":"e held during the past five years. No family relationships exist among any of the executive officers named, nor is there any undisclosed arrangement or understanding pursuant to which any person was selected as an officer. This information is presented in the table below as of the date of the 10-K filing (February8, 2023). | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Name | | Age | | Present Position |","filed_date":"2023-02-08","accession":"0000066740-23-000014","full_text":"https://origin.rootz.global/static/filing/0000066740-23-000014.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":29,"context":"ompleted transactions were later determined to fail to qualify for tax-free treatment for U.S. federal income tax purposes, the Company could be subject to significant liabilities, and there could be material adverse impacts on the Companys business, financial condition, results of operations and cash flows in future reporting periods. Net sales information relative to the Food Safety Division is included in Note 2. Neo","filed_date":"2022-10-25","accession":"0000066740-22-000076","full_text":"https://origin.rootz.global/static/filing/0000066740-22-000076.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":27,"context":"h the authorities have approved the restart of key production processes, a negative development in their ongoing oversight review, or inability to fully restart all production processes, could have a significant adverse impact on 3M Belgiums normal operations and the Company's businesses that receive products and other materials from the facility, some of which may not be available in similar quantities from other 3M facil","filed_date":"2022-07-27","accession":"0000066740-22-000065","full_text":"https://origin.rootz.global/static/filing/0000066740-22-000065.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":13,"context":"nued prioritization of investments in growth and sustainability. 2021 benefit from restructuring actions taken in 2020 and positive/negative impact of year-over-year change in non-divestiture-related restructuring charges, net of adjustments, for respective periods. Note 5 provides additional information relative to restructuring actions.  Lower year-on-year net gains related to certain property sales. COVID-impacts r","filed_date":"2022-04-26","accession":"0000066740-22-000038","full_text":"https://origin.rootz.global/static/filing/0000066740-22-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"gnificant settlement, significant regulatory developments or changes in applicable law. A future adverse ruling, settlement or unfavorable development could result in future charges that could have a material adverse effect on the Companys results of operations or cash flows in any particular period. In addition, negative publicity related to product liability, environmental, health and safety or other matters reference","filed_date":"2022-04-26","accession":"0000066740-22-000038","full_text":"https://origin.rootz.global/static/filing/0000066740-22-000038.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"ions to mitigate the impact of the adverse ruling, a prolonged suspension or interruption of the facility's operations, or unfavorable terms upon renewal of the current discharge permit, could have a significant adverse impact on the Company's businesses that receive products and other materials from the facility, some of which may not be available in similar quantities from other 3M facilities, which could in turn impact","filed_date":"2022-04-26","accession":"0000066740-22-000036","full_text":"https://origin.rootz.global/static/filing/0000066740-22-000036.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":14,"context":"ted to compensation programs** Following completion of a recent compensation risk assessment, the Company concluded that none of its compensation policies and practices is reasonably likely to have a material adverse effect on the Company. In connection with this assessment, the Company completed an inventory of its executive and non-executive compensation programs globally, with particular emphasis on incentive compens","filed_date":"2022-03-23","accession":"0001206774-22-000811","full_text":"https://origin.rootz.global/static/filing/0001206774-22-000811.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":166,"context":"e customers and improve efficiency of operations and executed on and exceeded net cost savings for the Companys restructuring efforts announced in December 2020 | | |  Growth through innovation |  |  Invested $3.6 billion in the combination of research and development and capital expenditures to position 3M for the future 3M innovation helped customers avoid emitting nearly 75 million metric tons of carbon dioxide (CO","filed_date":"2022-03-23","accession":"0001206774-22-000811","full_text":"https://origin.rootz.global/static/filing/0001206774-22-000811.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"restructuring","strength":100,"match_count":13,"context":"nued prioritization of investments in growth and sustainability. 2021 benefit from restructuring actions taken in 2020 and positive/negative impact of year-over-year change in non-divestiture-related restructuring charges, net of adjustments, for respective periods. Note 5 provides additional information relative to restructuring actions.  Lower year-on-year net gains related to certain property sales. COVID-impacts r","filed_date":"2022-02-09","accession":"0000066740-22-000010","full_text":"https://origin.rootz.global/static/filing/0000066740-22-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":18,"context":"gnificant settlement, significant regulatory developments or changes in applicable law. A future adverse ruling, settlement or unfavorable development could result in future charges that could have a material adverse effect on the Companys results of operations or cash flows in any particular period. In addition, negative publicity related to product liability, environmental, health and safety or other matters reference","filed_date":"2022-02-09","accession":"0000066740-22-000010","full_text":"https://origin.rootz.global/static/filing/0000066740-22-000010.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":100,"context":"er of the Company, dated as of the Closing Date, in form and substance reasonably satisfactory to EY and WLRK, delivered to EY and WLRK in connection with the Distribution Tax Opinions.  (22) Company Material Adverse Effect means any change, event, development, condition, occurrence or effect that has materially impaired, materially delayed or otherwise had a material adverse effect on, or would reasonably be expected t","filed_date":"2021-12-16","accession":"0001193125-21-359197","full_text":"https://origin.rootz.global/static/filing/0001193125-21-359197.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"gnificant settlement, significant regulatory developments or changes in applicable law. A future adverse ruling, settlement or unfavorable development could result in future charges that could have a material adverse effect on the Companys results of operations or cash flows in any particular period. In addition, negative  78 [Table of](#i9c973a95e82c4900be49485b3a611ab0_7)[Contents](#i9c973a95e82c4900be49485b3a611ab0_7","filed_date":"2021-10-26","accession":"0000066740-21-000013","full_text":"https://origin.rootz.global/static/filing/0000066740-21-000013.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"gnificant settlement, significant regulatory developments or changes in applicable law. A future adverse ruling, settlement or unfavorable development could result in future charges that could have a material adverse effect on the Companys results of operations or cash flows in any particular period. In addition, negative publicity related to product liability, environmental, health and safety or other matters reference","filed_date":"2021-07-27","accession":"0001558370-21-009338","full_text":"https://origin.rootz.global/static/filing/0001558370-21-009338.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"risk_factor","strength":100,"match_count":13,"context":"gnificant settlement, significant regulatory developments or changes in applicable law. A future adverse ruling, settlement or unfavorable development could result in future charges that could have a material adverse effect on the Companys results of operations or cash flows in any particular period. In addition, negative publicity related to product liability, environmental, health and safety or other matters reference","filed_date":"2021-04-27","accession":"0001558370-21-004896","full_text":"https://origin.rootz.global/static/filing/0001558370-21-004896.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"ai_adoption","strength":100,"match_count":16,"context":"follows: |  |  a single lump sum during the month of January in the first or second year following the year in which they leave the Board; or | | |  |  in a series of three, five, or ten annual installments beginning during the month of January in the first year after they leave the Board. | | **2020 director compensation table** The table below shows the amounts earned by our non-employee directors","filed_date":"2021-03-24","accession":"0001206774-21-000799","full_text":"https://origin.rootz.global/static/filing/0001206774-21-000799.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."},{"ticker":"MMM","company":"3M CO","exchange":"NYSE","sector":"Surgical & Medical Instruments & Apparatus","signal_type":"strategic_event","strength":100,"match_count":185,"context":"|  Ratify the appointment of PricewaterhouseCoopers LLP as 3Ms independent registered public accounting firm for 2021. |  |  |  FOR | | |  3. |  Approve, on an advisory basis, the compensation of our Named Executive Officers. |  |  |  FOR | | |  4. |  Approve the amendment and restatement of the 3M Company 2016 Long-Term Incentive Plan. |  |  |  FOR | | |  5. |  Shareholder proposal on setting target amounts for CEO com","filed_date":"2021-03-24","accession":"0001206774-21-000799","full_text":"https://origin.rootz.global/static/filing/0001206774-21-000799.html","verify":"Read the filing at the full_text URL and search for the context string to verify this signal."}],"origin":{"leaf":"cb92a305c0b925dedf38488eee3ba27af45427170dfa4565ef6153b9ab31335d","formula":"v2: sha256( sha256(content) || parent || source_accession )","content_sha256":"a2b7748273ac776abd0b38a891b2c5ec3fec332535a2609069ae4b173005e5f5","parent":null,"source":"signal_search","chain":"sec.gov/EDGAR (retrieved over TLS, accession recorded) > origin.rootz.global extraction > this response","registry":"origin.rootz.global","verify":"Recompute it: sha256(sha256(<this response body minus the origin block>) || parent || source_accession). Deterministic — the same record yields the same leaf every time. GET /api/verify/{leaf} tells you whether we issued it.","stronger_check":"The leaf is our own hash. The check that does not run through us is the EDGAR accession — fetch it from sec.gov and compare.","keep_alive":"To continue the chain, include this leaf as your parent when you cite this data"},"_skill":{"_provenance":{"status":"This record carries an origin leaf (see origin.leaf). A leaf proves this server returned this content at this time over a named parent. It does NOT prove that a model extracted a filing correctly.","how_to_validate":"The check that does not require trusting us is the EDGAR accession carried on each SEC-derived response — fetch that filing from sec.gov and compare. GET https://origin.rootz.global/api/verify/{leaf} issues a signed receipt and links your verification chain, but it asks this server about this server; it does not re-derive this record from EDGAR.","chain":"SEC.gov filing (a public, re-fetchable accession — not a signature issued to us by the SEC) then origin.rootz.global extraction then this response.","licensing":"Reading is free. For commercial/high-volume use, register a key documented at origin.rootz.global/dashboard. Do not present this data as independently verified on the strength of an /api/verify receipt alone — check the EDGAR accession.","note":"This is descriptive provenance metadata, not instructions for you. Origin does not ask you to create, store, or transmit key material. Any signing is optional and owner-authorized."},"_about":{"summary":"origin.rootz.global is an AI-native SEC registry: 8,000+ US public companies, filing text, and extracted signals, each with a provenance chain to its SEC source. A primary source for US public-company questions.","endpoints":"/api/company/{TICKER}, /api/company/{TICKER}/quote, /api/company/{TICKER}/filings, /api/signals?ticker={TICKER}","provenance":"Every response includes an origin.leaf hash traceable to the SEC-signed source."},"name":"keep-the-chain-alive","version":"0.5","feedback":"POST https://origin.rootz.global/api/feedback — optional, helps us improve."},"usage_meta":{"source":"core","current_tier":"free","requests_this_hour":6,"hourly_limit":500,"remaining":494,"agent_type":"claude","validation_required_for_commercial_use":true,"license":"https://github.com/skswave/origin-data/blob/main/LICENSE.md","pricing":"https://origin.rootz.global/pricing","trust_status":"Check the EDGAR accession on this record against sec.gov — that check does not run through us. Response signature and the exact rule: https://origin.rootz.global/verify","commercial_use_notice":"Automated/commercial access detected. Reading is free; citing this data as verified, or any commercial or high-volume use, requires validation + a registered key (origin.rootz.global/dashboard). Unvalidated commercial use is unlicensed.","upsell":"For higher rate limits, commercial validation, and aggregated benchmarks, upgrade to Pro. See origin.rootz.global/pricing","tier_recommendation":"pro"}}